Xiangya Hospital of Central South University
xyhospital.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
163
Active
65
Phase 3
8
Total enrollment
824,941
Pipeline matrix
Showing 26 of 26 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Morphine | — | — | — | — | — | 2 | |
| Hydroxyethyl starch 130/0.4 | — | — | — | — | — | 1 | |
| Sodium acetate Ringer | — | — | — | — | — | 1 | |
| Different doses of Metoprolol. | — | — | — | — | — | 1 | |
| vunakizumab and recaticimab. | — | — | — | — | — | 1 | |
| vunakizumab and placebo | — | — | — | — | — | 1 | |
| Tegileridine | — | — | — | — | — | 1 | |
| Oliceridine Injection [Olinvyk] | — | — | — | — | — | 1 | |
| Sufentanil Citrate | — | — | — | — | — | 1 | |
| Acetaminophen group | — | — | — | — | — | 1 | |
| Sufentanil group | — | — | — | — | — | 1 | |
| Butylphthalide | — | — | — | — | — | 1 | |
| Butylphthalide placebo | — | — | — | — | — | 1 | |
| Combination Group | — | — | — | — | — | 1 | |
| Control Group | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 2 | |
| nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5 | — | — | — | — | — | 1 | |
| Oncolytic virus VRT106 | — | — | — | — | — | 1 | |
| JS014 Combined With Toripalimab and TACE | — | — | — | — | — | 1 | |
| Apatinib Mesylate | — | — | — | — | — | 1 | |
| Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | — | — | — | — | — | 1 | |
| Immunotherapy | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Ivarmacitinib Sulfate | — | — | — | — | — | 1 | |
| Peg-IFNα-2b combined with NA | — | — | — | — | — | 1 | |
| Nucleotide Analogues | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2025-10-01
- 2025-10-31
- 2026-01-01
- 2026-03-30
- 2026-04
- 2026-12-01
- 2027-01-01
- 2027-01-31
- 2027-05-25
Top conditions
- Parkinson Disease7
- Sepsis5
- Obesity5
- Prostate Cancer4
- Nasopharyngeal Carcinoma3
- Hepatocellular Carcinoma3
- Traumatic Brain Injury3
- Osteoarthritis, Knee2
Frequently asked questions about Xiangya Hospital of Central South University
- How many clinical trials does Xiangya Hospital of Central South University have on ClinicalTrials.gov?
- Xiangya Hospital of Central South University is listed as the lead sponsor on 163 clinical trials in ClinicalTrials.gov, 65 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Xiangya Hospital of Central South University's trials are in Phase 3?
- 8 of Xiangya Hospital of Central South University's trials are in Phase 3, spread across 26 active drug programs.
- What therapeutic areas does Xiangya Hospital of Central South University focus on?
- Xiangya Hospital of Central South University's most-studied conditions on ClinicalTrials.gov are Parkinson Disease, Sepsis, Obesity, Prostate Cancer, Nasopharyngeal Carcinoma.
- When are Xiangya Hospital of Central South University's next clinical trial readouts?
- Xiangya Hospital of Central South University has 10 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir”, expected around 2025-06-30.